Embedding genetic testing in the metastatic prostate cancer pathway: understanding patient and physician perspectives.

ABSTRACT:

Aim

To understand how genetic (homologous recombination repair [HRR], including BReast CAncer [BRCA]) testing is being embedded in clinical practice and identify testing challenges given global approvals of poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPis) for metastatic prostate cancer (mPCa).

Methods

Data from two Adelphi Real World Prostate Cancer Disease Specific Programmes™ (DSPs; 2020 and 11/2022-7/2023) were analyzed and compared using appropriate bivariate tests.

Results

Genetic testing was performed among 45% (855/1899) of patients with mPCa (castration-sensitive [mCSPC]: 36%; castration-resistant [mCRPC]: 49%; HRR genes: 43% [34%; 47%]; BRCA: 42% [34%; 46%]). Testing increased from 2020: HRR genes by 17% (p < 0.01); BRCA by 18%

SUBMITTER: Jain R 

PROVIDER: S-EPMC12622337 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature